inventedin 1988. reinventedin 2015. - curasan ag · excellence team 3 dr. erwin amashaufer cfo dr....

Invented in 1988.Reinvented in 2015.

Company Presentation

August 2015

Our Mission

„Become a profitable player in regenerative medicine in our two core areas

dental and orthopedics.

Encourage a climate of innovation and internationality among our employees and

business partners.

Focus on doing a few things best rather than a broad range mediocre.“

Company Presentation, August 2015 2

Excellence Team

3

Dr. Erwin AmashauferCFO

Dr. Wolf-Dietrich HübnerMedical Director

Dr. Fabian PetersTechnical Director

Gregor SiebertDirector Marketing & Sales

Michael SchlenkCEO

Company Presentation, August 2015

New CEO since end of 2014

Michael Schlenk, CEO

Diplom-Kaufmann (Marketing, Psychology) of Hamburg University, DMBA (Finance, Intl. Marketing) of University of Bradford, UK

...more than 25 years of experience in the pharmaceutical industry:

� 1988: Sandoz (CH) Country Manager Asia-Pacific, Africa

� 1994: Abbott (A) CEO Austria

� 1999: Abbott (BRA) President and CEO Brazil

...since 2004 angel investor and CEO of two biotech startupsProBioGen and Centogene until June 2014.

...successful track record in turnaround situations on an international level (Big Pharma and Biotech).

4Company Presentation, August 2015

New Director Marketing & Sales since April

30 years of experience in the pharmaceutical industry:

� 1985: Abbott (D) Sales Representative

� 1999: Abbott (D) Head of hospital products and medical nutrition

� 2004: Hikma (UK) responsible for strategic expansion & product innovations Germany / Europe

� 2010: Pfizer (UK) Vice President Hospital Europe

� 2014: GL Pharma (A) Head of Marketing & Sales

...strong network in European Big Pharma and Hospital Industry

...international Sales & Marketing experience with proven track record

5

Gregor SiebertDirector Marketing & Sales


High potential key products...

6

Granules PasteBlock Forms

Main Trademark

Cerasorb™ Osbone™Ceracell™ Osseolive™

Moldable Foam PuttyFlexible Foam

� unique, highly competitive portfolio of superior synthetic bone graft substitutes � owner of 9 patents� further 10 patent applications


Evolution in technology leadership


1997: Cerasorb- Round granules- Micropores- Porosity 35%- Resorption

approx. 6 months

2003: Cerasorb M- Polygonal morsels- Micro- meso- and

macropores- Porosity 65%- Resorption approx.

4 months

2010: Ceracell- Polygonal morsels- Spongious

structure- Open-cellular- Silicate addition- Porosity 80%- Faster resorption

2011: Osseolive- Glass ceramic- Open cellular- Silicate addition- Porosity 80%- High mechanical stability- Faster resorption by different material

Fields of application Dental / Ortho

8

� diversity in product features allows individual therapies � more than 1.5 million units of Cerasorb in the market prove high level of

resorbability of the product without contraindications � multiple fields of application in dental and orthopedic surgery

OMF SurgeryHand / Foot /

Trauma Surgery Spine Surgery Joint Replacement


Worldwide BGS market 2015

9

33%

47%

20%

ROW

€368m

Europe

USA

71%

8%

21%

ROW

Europe

USA

€1.045m

Ortho Dental

Source: iData, espicom, Orthoknow, company estimates

4-6 %growth

p.a.


Worldwide Sales Activities


Successful 1st Quarter

11

in EUR thousand Q1 2015 Q1 2014 ∆ [abs.] ∆ [%]

Revenues incl. changes in inventories 1,666 1,628 38 2.3%

EBITDA -70 -221 151 68.3%

EBIT -159 -312 153 49.0%

Result for the quarter -189 -324 135 41.7%

Earnings per share -0.02 -0.04

in EUR thousand 31/03/15 31/12/14 ∆ [abs.] ∆ [%]

Operating Cashflow -475 -456 -19 -4.2%

Cash and cash equivalents 1,064 1,552 -488 -31.4%

Employees 33 32 +1 3.1%


Settlement with Stryker in June 2015

12

Out-of-court settlement with Stryker on June 18th, 2015

Settlement payment of4,5 mEUR

Optional OEM Productionby curasan for Stryker

Sustantial improvement of financial situation and instant reduction of

liabilities

Chance of further revenue streams without additional risk


Outlook 2015

13

� Focus on Marketing & Sales

� sustainable and smart selective investments

� Revenues to grow faster than net result

� Investment accelerate growth from 2016 onwards

Revenues (gross)

Net result

6.3 mEUR - 6.9 mEUR

-1.2 mEUR - -1.6 mEUR


Targeted sales strategy

14

Marketing without structure

Sales revenues of partnersmostly intransperent

Basis of trust

with sales partners

Best sales channelfor every single market

Country specific Marketing &

Sales concepts

Establish market oriented

Controlling tools

WIN-WIN attitude towardssales partners

Opportunistic choice of sales partners

Focus on growth marketsin close distance


Investment in Human Capital

15

Q2

� Investment in Human Capital decisive� Focus on Sales & Marketing for sustainable revenue stimulation

Q3 Q4 Q1 Q2 Q3

3. EXPORT MANAGER (MENA)

2. EXPORT MANAGER (Europe)

3. PRODUCT MANAGER

PROJECT CONTROLLER

4. PRODUCT MANAGER

2015 2016


Operating Break-even until end of 2016

16

� Target revenue 2016: 7.3 to 8.0 mEUR

� Operating Break-even on monthly basis

during Q 4 2016


Strategic Outlook - Europe

17

Growth until 2016:

Germany +12 %

EU 6 (ex GER) +20 %

EU others +22 %


Strategic Outlook - World

18

Asia Pacific+23 %

Eastern Europe:+6 %

Latin America:+6 %

MENA:+78 %

USA:+25 %


Focus on growth regions

19

Focus on growth regions in

close distance:

UK:

� so far under developed

� attractive potential

� so far no sales partnerships

Middle East

� very dynamic growth

� very good network

within curasan

� so far no sales partnerships


Summary

20

Assets

� curasan has excellent, well documented, safe products without side effects

� curasan owns state-of-the-art production with over-capacities

� Very experienced registration department with remarkable track record

� Potential windfall profits from Stryker deal

Needs

� Invest in market understanding

� Modernize Marketing and Sales

� Focus portfolio, evaluate internal and external product opportunities

� Reach profitability

Invest in marketing and products


Disclaimer

21

This presentation does not constitute an stock offering in the sense of a legalprospectus according to the laws of publically traded companies in Germany. This

presentation is not an offer to sell nor does it indicate an offer to purchase or issueshares of curasan AG. It is solely intended to provide additional information. Anyother use, duplication, or distribution of this document or the information contained

within is strictly prohibited.

This presentation contains „forward looking statements” regarding curasan AG,

including opinions, estimates and projections regarding curasan’s financial position,business strategy, plans and objectives of management and future operations. Suchforward looking statements involve known and unknown risks, uncertainties and

other important factors that could cause the actual results, performance orachievements of curasan AG to be materially different from future results,

performance or achievements expressed or implied by such forward lookingstatements. These forward looking statements speak only as of the date of thispresentation and are based on numerous assumptions which may or may not prove

to be correct.

No representation or warranty, express or implied, is made by curasan AG with

respect to the fairness, completeness, correctness, reasonableness or accuracy ofany information and opinions contained herein, including but not limited to theplans, business relationships, financial situation, market conditions, competition,

future strategies, and regulatory assumptions. The information is this presentationis subject to change without notice, it may be incomplete or condensed, and it may

not contain all material information concerning curasan AG. curasan AG undertakesno obligation to publicly update or revise and forward looking statements or otherinformation stated herein, whether as a result of new information, future events or

otherwise.

curasan AG reserves the right to adjust or change these forward looking statements

at any time should there be changes in relevant factors. The forward lookingstatements from studies conducted by third parties could prove to be incorrect. The

use of data from third party studies or reports serves solely to provide additionalinformation and does not indicate or imply accuracy or agreement with such data,claims, opinions or conclusions. curasan AG does not warranty or assume

responsibility for the selection, completeness, or accuracy of third party studies orinformation.

Kleinostheim

Lindigstraße 4

63801 Kleinostheim

Germany

T: +49 6027 40 900 22

F: +49 6027 40 900 29

Michael Schlenk

CEO

[email protected]

e

Dr. Erwin Amashaufer

Financial Director

[email protected]

Gregor Siebert

Director Marketing & Sales

[email protected]

Background curasan AG


inventedin 1988. reinventedin 2015. - curasan ag · excellence team 3 dr. erwin amashaufer cfo dr....

Documents